Grace Therapeutics (GRCE) EBT (2019 - 2026)
Grace Therapeutics (GRCE) posted EBT of -$2.9 million for Q1 2026, down 24.32% sequentially from -$2.3 million in Q4 2025, and down 653.4% YoY from $520054.9 in Q1 2025.
Grace Therapeutics (GRCE) EBT (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported EBT for 8 years, with the latest figure at -$2.9 million in Q1 2026.
- Quarterly EBT fell 653.4% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.5 million (up 25.64% YoY) and the FY2026 annual result came in at -$9.5 million, up 25.64% from the prior year.
- EBT eased to -$2.9 million in Q1 2026 per GRCE's latest filing, from -$2.3 million in the prior quarter.
- Over five years, EBT peaked at -$382000.0 in Q1 2025 and troughed at -$38.0 million in Q1 2023.
- A 5-year average of -$5.5 million and a median of -$4.1 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2025: EBT sank 733.88% in 2023, then jumped 90.58% in 2025.
- Over 5 years, EBT stood at -$4.2 million in 2022, then jumped by 37.57% to -$2.6 million in 2023, then tumbled by 83.15% to -$4.8 million in 2024, then surged by 51.37% to -$2.3 million in 2025, then decreased by 24.32% to -$2.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$2.9 million, -$2.3 million, and -$938000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | -15.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.79 Mn |
| Mar 31, 2026 | -2.88 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -938,000.00 |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | -382,000.00 |
| Dec 31, 2024 | -4.76 Mn |
| Sep 30, 2024 | -4.28 Mn |
| Jun 30, 2024 | -3.34 Mn |
| Mar 31, 2024 | -4.06 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Sep 30, 2023 | -3.72 Mn |
| Jun 30, 2023 | -4.31 Mn |
| Mar 31, 2023 | -37.96 Mn |
| Dec 31, 2022 | -4.16 Mn |
| Sep 30, 2022 | -5.08 Mn |
| Jun 30, 2022 | -4.77 Mn |
| Mar 31, 2022 | -4.55 Mn |
| Dec 31, 2021 | -3.78 Mn |
| Sep 30, 2021 | 981,000.00 |